IPO issue has been subscribed 11 times on 3rd day till the time of writing
Indegene provides many services to life science companies.
It claims to be only company providing such diverse services in this segment.
North America and Europe is company's target market.
Life sciences operations spend has grown at a CAGR of approximately 6.7% from 2020 to 2022
Life science operations market is growing at fast pace presenting Indegene with a large room to grow.
Revenue grew at a CAGR of 54.5% between FY21-23 where EBITDA grew at 31.1% CAGR and PAT grew at 19.7% CAGR betweenFY21 andFY23.
At the upper price band of ₹452 company is valued at 34x P/E (taking the FY24 EPS estimates)
Know more about the IPO, click on the below link,
https://finminutes.com/indegene-ipo10-key-details-and-should-you-subscribe/